The rise in popularity of consumer-driven healthcare (CDHC) will challenge HMOs to be at the top of their game, say industry watchers.
The rise in popularity of consumer-driven healthcare (CDHC) will challenge HMOs to be at the top of their game, say industry watchers.
In order to remain relevant, HMOs will need to focus on the consumer choice aspect of the rapidly evolving CDHC market, according to Shawn Jenkins, CEO of Benefitfocus, a provider of CDHC software and services located in Charleston, S.C. "HMOs have done a good job managing healthcare costs for employers and health plans," Jenkins says. "Consumer-driven plans are going to challenge HMOs for market share."
Commentary is independent of source data
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Women PCPs Have Equal or Better Medicare Patient Outcomes Than Men PCPs in Value-Based Care Model
June 24th 2025Women primary care providers (PCPs) treating Medicare patients in a value-based care model achieved better patient outcomes and earned more per patient than male counterparts, despite receiving equal patient satisfaction ratings, highlighting a potential for value-based payment to help close the gender pay gap.
Read More
A Progress Report on Chronic GVHD. The Grades Are Not So Great
June 24th 2025There has been no or some progress in most areas since a National Institute of Health consensus development project in 2020, according to a group of experts. But exception is important: Prevention of moderate or severe chronic graft-vs.-host disease.
Read More